Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (NASDAQ: EDIT) announced the acceptance of new preclinical data for presentation at the European Hematology Association (EHA) 2025 Congress in Milan. The study, conducted in non-human primates, demonstrates promising results for their in vivo hematopoietic stem cell (HSC) gene editing program targeting sickle cell disease and beta thalassemia.

Key findings include high-efficiency HSC delivery, therapeutically relevant editing levels in the HBG1/2 promoter region exceeding 25% threshold with a single dose, and favorable biodistribution using Editas' targeted lipid nanoparticle (tLNP) technology. The data shows significant liver de-targeting compared to standard LNPs, supporting further development of their proprietary HSC-tLNP platform.

In non-human primates, a single intravenous dose achieved up to 47% HBG1/2 editing levels in HSCs. In humanized mice, the treatment reached 48% editing in long-term HSCs. Both results exceeded the 25% threshold required for therapeutic benefit.

The company's tLNP formulation showed improved liver de-targeting compared to standard LNPs, and utilizes proprietary AsCas12a technology for high-efficiency editing while minimizing off-target effects. The approach mimics naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH).

• ~70% maximal liver editing and >80% disease biomarker reduction in mouse models
• >50% target gene editing and >15-fold protein upregulation in cynomolgus monkey hepatocytes

Editas Medicine (NASDAQ: EDIT) announced that the U.S. Court of Appeals for the Federal Circuit has partially affirmed and partially vacated the Patent Trial and Appeal Board's (PTAB) previous decision regarding CRISPR/Cas9 patent interference. The case involves patents between the University of California, University of Vienna, and Emmanuelle Charpentier versus the Broad Institute.

The company emphasized that its in-licensed CRISPR/Cas12a patents are unaffected by this decision. Editas holds exclusive licenses to Harvard and Broad Institute's Cas9 patent estates for human medicine development. The company maintains a robust IP portfolio including fundamental patents for both CRISPR/Cas12a and CRISPR/Cas9 gene editing in human cells across multiple jurisdictions including the US, Europe, China, and Japan.

Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced it will release its Q1 2025 financial results on May 12, 2025 through a press release and SEC filings. The company has discontinued its practice of hosting quarterly financial results conference calls.

Additionally, Editas management will participate in the Bank of America Global Healthcare Conference in Las Vegas on May 13, 2025 at 5:15 p.m. PT in a fireside chat format. The presentation will be accessible via webcast on the company's website, with a replay available for approximately 30 days.

Editas Medicine (Nasdaq: EDIT) announced the acceptance of five abstracts for presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), scheduled for May 13-17, 2025, in New Orleans.

The presentations include:

• An oral presentation on in vivo preclinical data using targeted lipid nanoparticles for HBG1/2 promoter editing
• Preclinical proof of concept for a liver target using CRISPR editing
• Results from mouse and non-human primate studies showing high levels of target gene editing in the liver
• Data on guide modification and targeting improvements for better gene editing outcomes

Linda C. Burkly, Executive Vice President and Chief Scientific Officer, highlighted the company's progress in developing in vivo medicines. The research demonstrates their ability to increase protein levels to address diseases caused by loss of function or mutations through gene upregulation editing strategy. Their targeted lipid nanoparticle delivery system shows promise for multiple tissue applications using a 'plug 'n play' approach.

Editas Medicine (Nasdaq: EDIT) announced a leadership transition as Chief Financial Officer Erick J. Lucera will step down effective March 28, 2025, to pursue an external opportunity. Amy Parison, current Senior Vice President of Finance, has been appointed as the new CFO.

Parison brings over 18 years of financial, accounting, and business development experience in life sciences to the role. During her two-and-a-half-year tenure at Editas, she has been instrumental in equity financings, licensing transactions, and royalty monetization. Her previous experience includes positions at Rubius Therapeutics as Corporate Controller and various roles at Vertex Pharmaceuticals.

CEO Gilmore O'Neill praised Parison's financial decision-making, accounting acumen, and team leadership abilities, while acknowledging Lucera's contributions in positioning Editas financially and developing talent.

Editas Medicine (NASDAQ: EDIT) reported its Q4 and full year 2024 financial results, highlighting progress in its in vivo gene editing programs. The company remains on track to declare two development candidates in mid-2025: one for hematopoietic stem cells (HSCs) and another for liver cells.

Financial highlights include:

• Q4 2024 net loss of $45.4 million ($0.55 per share)
• Full year 2024 net loss of $237.1 million ($2.88 per share)
• Cash position of $269.9 million as of December 31, 2024
• Operational runway extended into Q2 2027

The company discontinued development of reni-cel program in December 2024, resulting in a 65% workforce reduction. Restructuring charges of $12.2 million were recorded in Q4 2024. The company's strategic focus has shifted to becoming a leader in in vivo gene editing, with promising preclinical data showing potential for gene upregulation across multiple tissues.